Y-mAbs Therapeutics, Inc. (YMAB) has announced strategic business updates and 2025 priorities, positioning the company for long-term growth and success. The company's mission remains focused on bringing important new cancer therapies to patients as quickly as possible. With the successful commercial launch of DANYELZA, Y-mAbs has positively impacted the lives of children with high-risk relapsed/refractory neuroblastoma, providing hope for a better future.

The company has internally realigned its operations with the establishment of two business units: Radiopharmaceuticals and DANYELZA. This strategic move aims to optimize internal resources, provide flexibility, and accelerate clinical execution while driving commercial growth of DANYELZA. By focusing on these two distinct business units, Y-mAbs expects to expand its radiopharmaceutical capabilities, accelerate clinical execution, further improve capital efficiencies, and better align strategic priorities.

Y-mAbs reports preliminary estimated unaudited Total Net Revenue of approximately $88 million for the year ended December 31, 2024, within the Full Year 2024 top line guidance range. The company's cash position of approximately $67 million as of December 31, 2024, is anticipated to support operations into 2027. This robust cash position provides operational flexibility and allows the company to invest in strategic initiatives, such as the optimization of the DANYELZA commercial team, to drive long-term revenue growth.

The company's GD2-SADA Phase 1 trial has dosed 21 patients across six sites, showing promising tolerability with no dose-limiting toxicities. Part A data presentation is expected in the second quarter of 2025. The realignment includes a workforce reduction of up to approximately 13%, depending on whether a portion of impacted employees accept newly created positions, and intends to move some roles from Denmark to the U.S. to more efficiently coordinate the advancement of its radiopharmaceutical platform, with a small adjustment of the DANYELZA commercial team to focus the team around potential growth opportunities within the anti-GD2 market.

Key 2025 milestones include presenting GD2-SADA optimization data, dosing the first patient in CD38-SADA Phase 1 trial in Q1, and potential DANYELZA marketing approval in new ex-U.S. markets. The company's strategic bifurcation positions it to capture value in both established and emerging markets. DANYELZA's unique position as the only FDA-approved treatment for high-risk relapsed/refractory neuroblastoma provides a stable revenue base. The optimization of the commercial team around GD2 market opportunities suggests untapped potential in the current indication.

The radiopharmaceuticals unit's focus on the SADA PRIT platform represents a significant market opportunity. The platform's advantages in physician adoption and reduced infrastructure requirements could accelerate market penetration. The planned pipeline expansion into new high-value target indications in Q2 2025 could substantially expand the addressable market.




In conclusion, Y-mAbs Therapeutics' strategic business update and 2025 priorities position the company for long-term growth and success. By focusing on the Radiopharmaceuticals and DANYELZA business units, Y-mAbs aims to optimize internal resources, accelerate clinical execution, and drive commercial growth. With a strong financial performance and robust cash position, the company is well-equipped to capitalize on emerging market opportunities and continue its mission to improve and extend people's lives.